13.46  -0.33 (-2.39%)		09-16 16:00
Open: 13.44 High: 13.62 Volume: 31,207		Pre. Close: 13.79 Low: 13.38 Market Cap: 2,348(M)

Short term
Mid term
Targets	6-month :	16.73	1-year :	19.54
Resists	First :	14.32	Second :	16.73
Pivot price	13.04
Supports	First :	12.76	Second :	11.8
MAs	MA(5) :	13.36	MA(20) :	12.89
	MA(100) :	11.9	MA(250) :	13.62
MACD	MACD :	0.4	Signal :	0.3
%K %D	K(14,3) :	72.7	D(3) :	64.1
RSI	RSI(14): 58
52-week	High :	17.62	Low :	9.77

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ HCM ] has closed below upper band by 36.6%. Bollinger Bands are 64.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	13.63 - 13.71	13.71 - 13.78
Low:	13.2 - 13.29	13.29 - 13.36
Close:	13.34 - 13.47	13.47 - 13.6

HUTCHMED (China) Limited is a biopharmaceutical firm dedicated to the discovery, advancement, and marketing of innovative targeted and immune-based treatments for various cancers and immune-related disorders. Its operations are divided into two main areas: Oncology/Immunology and a segment encompassing Other Ventures. The company's reach extends from Hong Kong globally. Among its pipeline, HUTCHMED is developing Savolitinib, an inhibitor targeting non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC). Another key therapeutic, Fruquintinib, is an inhibitor being investigated for its efficacy in CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and a range of other gastrointestinal and solid tumors. Furthermore, the company's portfolio includes Surufatinib, an inhibitor applicable to numerous conditions such as neuroendocrine tumors (NETs - both pancreatic and non-pancreatic), biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, gastric cancer (GC), thyroid cancer, endometrial cancer (EMC), NSCLC, and general solid tumors. HMPL-523, a spleen tyrosine kinase inhibitor, is designed to treat hematological cancers and specific chronic immune conditions, while HMPL-689 targets the isoform PI3Kd (phosphoinositide 3'-kinase delta). Additional compounds in development include Tazemetostat, an EZH2 inhibitor indicated for specific epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor showing promise for hematological malignancies, gliomas, and solid tumors; HMPL-760, which functions as a Bruton's tyrosine kinase inhibitor; and HMPL-453, an inhibitor aimed at intrahepatic cholangiocarcinoma. The pipeline also features HMPL-295 for solid tumors, HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors, alongside Epitinib (HMPL-813) and Theliatinib (HMPL-309), both of which act as inhibitors. HUTCHMED maintains strategic collaboration agreements with a number of partners, including AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The entity, established in 2000 and headquartered in Central, Hong Kong, was previously identified as Hutchison China MediTech Limited before officially adopting its current name, HUTCHMED (China) Limited, in May 2021.

Mon, 07 Sep 2026
HUTCHMED (China) Limited (HCM) Discusses Strategic Partnership With GSK and Licensing of Oncology Asset A830 - Slideshow (NASDAQ:HCM) 2026-09-07 - Seeking Alpha

Thu, 03 Sep 2026
GSK backs HUTCHMED (China) (HCM) cancer drug in deal topping $1 billion - Stock Titan

Thu, 03 Sep 2026
HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy - Yahoo Finance

Thu, 03 Sep 2026
Panmure and Cavendish reiterate buy on Hutchmed after GSK deal - Proactive financial news

Thu, 03 Sep 2026
HUTCHMED shares jump 17% on US$1.3 billion GSK cancer drug deal - Proactive financial news

Wed, 02 Sep 2026
GSK agrees to pay $110 million for HUTCHMED cancer-drug rights - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	174 (M)
Shares Float	105 (M)
Held by Insiders	0 (%)
Held by Institutions	2.5 (%)
Shares Short	170 (K)
Shares Short P.Month	194 (K)

EPS	0.1
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	7.26
Profit Margin	3.2 %
Operating Margin	0.3 %
Return on Assets (ttm)	-1.3 %
Return on Equity (ttm)	1.4 %
Qtrly Rev. Growth	0.2 %
Gross Profit (p.s.)	0.42
Sales Per Share	3.15
EBITDA (p.s.)	-0.12
Qtrly Earnings Growth	-96.5 %
Operating Cash Flow	20 (M)
Levered Free Cash Flow	-19 (M)

PE Ratio	134.59
PEG Ratio	0
Price to Book value	1.85
Price to Sales	4.26
Price to Cash Flow	114.34

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.